
Maxim Group analyst Anthony Vendetti has maintained their bullish stance on BHST stock, giving a Buy rating on November 16. Anthony Vendetti’s Buy rating is based on several factors, including
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| BHST | BioHarvest Sciences | 1.30 | -4.67 | -78.22% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.30 | -78.22% |

Maxim Group analyst Anthony Vendetti has maintained their bullish stance on BHST stock, giving a Buy rating on November 16. Anthony Vendetti’s Buy rating is based on several factors, including

In a report released today, Amit Dayal from H.C. Wainwright maintained a Buy rating on BioHarvest Sciences, with a price target of $14.00. Amit Dayal has given his Buy rating

Bioharvest Sciences, Inc. (($BHST)) has held its Q3 earnings call. Read on for the main highlights of the call. BioHarvest Sciences’ earnings call conveyed a cautious but constructive tone. Management

Bioharvest Sciences, Inc. (BHST) is scheduled to report 3rd quarter earnings on 11/12/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Bioharvest Sciences, Inc. to post earnings

An update from BioHarvest Sciences ( ($BHST) ) is now available. BioHarvest Sciences has scheduled the release of its third-quarter 2026 financial results for November 12, 2026, ahead of the

BioHarvest Sciences ( ($BHST) ) just unveiled an announcement. BioHarvest Sciences has advanced its proprietary Olive Cell composition, derived from Olea europaea fruit, to full commercial readiness, positioning it for

BioHarvest Sciences ( ($BHST) ) has issued an announcement. BioHarvest Sciences, a biotechnology firm specializing in plant-derived ingredients via its Botanical Synthesis platform, is working with Tate & Lyle, a

An update from BioHarvest Sciences ( ($BHST) ) is now available. BioHarvest Sciences announced on September 29, 2026 that its board has approved a normal course issuer bid share repurchase

An announcement from BioHarvest Sciences ( ($BHST) ) is now available. BioHarvest Sciences has launched a normal course issuer bid, authorizing the repurchase of up to 5% of its outstanding

BioHarvest Sciences ( ($BHST) ) has shared an announcement. BioHarvest Sciences has introduced single‑dose VINIA Daily Chews, a new chewable format of its proprietary red‑grape cell composition, on September 15,
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 29, 2027TBA | $29.92M | ― | ― | 0.35 | -2.36 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.